Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas

Anticancer Research

Volumn 19, Issue 5 C, 1999, Pages 4375-4378

  Oshiba, Gen ^a   Kijima, Hiroshi ^a   Himeno, Shinji ^a   Kenmochi, Takahiro ^a   Kise, Yoshifumi ^a   Tanaka, Hikaru ^a   Nishi, Takayuki ^a   Chino, Osamu ^a   Shimada, Hideo ^a   Machimura, Takao ^a   Tsuchida, Takashi ^a   Nakamura, Masato ^a   Ueyama, Yoshito ^a   Tanaka, Makiko ^a   Tajima, Tomoo ^a   Makuuchi, Hiroyasu ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophagus; Immunohistochemistry; Lymph node metastasis; Squamous cell carcinoma; Thrombospondin

Indexed keywords

THROMBOSPONDIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STROMA; VEIN;

AGED; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; STROMAL CELLS; THROMBOSPONDIN 1;

EID: 19244385544     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Parenti AR, Rugge M, Shiao YH, Ruol A, Ancona E, Bozzola L, and Ninfo V: bcl-2 and p53 immunophenotypes in pre-invasive, early and advanced oesophageal squamous cancer. Histopathology 31: 430-435, 1997.
2. Tahara E: Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer 75: 1410-1417, 1995.
3. Sugimachi K, Sumiyoshi K, Nozoe T, Yasuda M, Watanabe M, Kitamura K, Tsutsui S, Mori M, and Kuwano H: Carcinogenesis and histogenesis of esophageal carcinoma. Cancer 75: 1440-1445, 1995.
4. Watanabe H, Jass JR, and Sobin LH : Histological classification of oesophageal tumors. In: Histrological typing of oesophageal and gastric tumours.Springer-Verlag, Berlin 1992.
5. Chino O, Makuuchi H, Machimura T, Mizutani K, Shimada H, Kanno K, Nishi T, Tanaka H, Sasaki T, Tajima T, Mitomi T, and Sugihara T: Treatment of esophageal cancer in patients over 80 years old. Surg Today 27: 9-16, 1997.
6. Makuuchi H, Shimada H, Mizutani K, Chino O, Nishi T, Tanaka H, Machimura T, Mitomi T, and Osamura Y: Clinical pathological analysis of surgically resected superficial esophageal carcinoma to determine criteria for deciidng on treatment strategy. Diag Therap Endosc 3: 211-220, 1997.
7. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, and Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospodin. Proc Natl Acad Sci USA 87: 6624-6628, 1990.
8. Jaffe EA, Ruggiero JT, Leung LLK, Doyle MJ, McKeon-Longo PJ, and Mosher DF: Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix. Proc Natl Acad Sci USA 80: 998-1002, 1983.
9. Falkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27-31, 1995.
10. Robert DD: Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 10: 1183-1191, 1996.
11. Bornstein P: Thrombospodins: structure and regulation of expression. FASEB J 6: 3290-3299, 1992.
12. Taraboletti G, Roberts D, Liotta LA, and Giavazzi R: Platelet thrombospodin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor. J Cell Biol 111: 765-772, 1990.
13. Taraboletti G, Roberts DD, and Liotta LA: Thrombospodin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domeins. J Cell Biol 105: 2409-2415, 1987.
14. Nickoloff BJ, Mitra RS, Riser BL, Dixit VM, and Varani J: Modulation of keratinocyte motility. Correlation with production of extracellular matrix molecules in response to growth promoting and antiproliferative factors. Am J Pathol 132: 543-551, 1988.
15. Reed MJ, Puolakkainen P, Lane TF, Dickerson D, Bornstein P, and Sage EH: Differential expression of SPARC and thrombospodin 1 in wound repair: immunolocalization and in situ hybridization. J Histochem Cytochem 41: 1467-1477, 1993.
16. Liska DJ, Hawkins R, Wikstrom K , and Bornstein P: Modulation of thrombospodin expression during differentiation of embryonal carcinoma cell. J Cell Physiol 158: 495-505, 1994.
17. Corless CL, Mendoza A, Collins T, and Lawler J: Colocalization of thrombospodin and syndecan during development. Dev Dyn 193: 346-358, 1992.
18. Varani J, Dixit VM, Fligiel SE, McKeever PE, and Carey TE: Thrombospodin-induce attachment and spreading of human squamous carcinoma cell. Exp Cell Res 167: 376-390, 1986.
19. Roberts DD, Sherwood JA, and Ginsburg V: Platelet thrombospodin mediates attachment and spreding of human melanoma cell. J Cell Biol 104: 131-139, 1987.
20. Dameron KM, Volpert OV, Tainsky MA, and Bouck N: Control of angiogenesis in fibroblast by p53 regulation of thrombospodin-1. Science 265: 1582-1584, 1994.
21. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, and Steeg PS: Transfection of thrombospodin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54: 6504-6511, 1994.
22. Sobin LH, and Wittekind C: Oesophagus. In: TNM classification of malignant tumours. Wiley-Liss, Inc., New York, pp54-58, 1997.
23. Grossfeld GD, Shi SR, Ginsberg DA, Rich KA, Skinner DG, Taylor CR, and Cote RJ: Immunohistochemical detection of thrombospodin-1 in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 44: 761-766, 1996.
24. Avrameas S, and Ternynck T: Peroxidase Labelled antibody and Fab conjugates with enhanced intracellular penetration. Immunochemistry 8: 1175-1179, 1971.
25. Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, and Gasic GJ: Thrombospodin, a potentiator of tumor cell metastasis. Cancer Res 47: 4130-4133, 1987.
26. Wong SY, Purdie AT, and Han P: Thrombospodin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am J Pathol 140: 1473-1482, 1992.
27. Castle V, Varani J, Fligiel S, Prochownik EV, and Dixit V: Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 87: 1883-1888, 1991.
28. Castle VP, Ou X, O'Rourke K, and Dixit VM: High level thrombospodin 1 expression in two NIH 3T3 cloned lines confers serum-and anchorage-independent growth. J Biol Chem 268: 2899-2903, 1993.
29. Tuszynski GP, and Nicosia RF: Localization of thrombospodin and its cysteine-serine-valine-threonine-cysteine-glycin-specific receptor in human breast carcinoma. Lab Invest 70: 228-233, 1994.
30. Clezardin P, Frappart L, Clerget M, Pechoux C, and Delmas PD: Expression of thrombospodin (TSP 1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 53: 1421-1430, 1993.
31. Yamashita Y, Sendo S, Hosokawa T, Tuszynski G, Kurohiji T, Beppu R, Shinohara T, Kinugasa T, and Shirakusa T: Exogenous thrombospondin stimulates the proliferation of non-thrombospondin-producing cells. Int J Oncol 13: 355-359, 1998.
32. Zabrenetzky V, Harris CC, Steeg PS, and Roberts DD: Expression of the extracellular matrix molecule thrombospodin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell line. Int J Cancer 59: 191-195, 1994.
33. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, and Cote RJ: Thrombospodin expression in bladder cancer: association with p53 alteration, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 89: 219-227,1997.